Reuters logo
BRIEF-Kadmon Holdings Inc says dosed first patient in a phase 1 clinical study to evaluate safety and tolerability of Tesevatinib​
September 25, 2017 / 8:47 PM / 3 months ago

BRIEF-Kadmon Holdings Inc says dosed first patient in a phase 1 clinical study to evaluate safety and tolerability of Tesevatinib​

Sept 25 (Reuters) - Kadmon Holdings Inc

* Kadmon Holdings Inc - ‍on September 13, 2017, co dosed first patient in a phase 1 clinical study to evaluate safety and tolerability of Tesevatinib​ Source text: (bit.ly/2yoVQas) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below